Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice

Mostrar otras versiones (1)

Improving clinical care for individuals infected with SARS-CoV-2 variants is a global health priority. Small-molecule antivirals like remdesivir (RDV) and biologics such as human monoclonal antibodies (mAbs) have demonstrated therapeutic efficacy against SARS-CoV-2, the causative agent of coronaviru...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinez, David R., Schäfer, Alexandra, Leist, Sarah R., Li, Dapeng, Gully, Kendra, Yount, Boyd, Feng, Joy Y., Bunyan, Elaine, Porter, Danielle P., Cihlar, Tomas, Montgomery, Stephanie A., Haynes, Barton F., Baric, Ralph S., Nussenzweig, Michel C., Sheahan, Timothy P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270748/
https://www.ncbi.nlm.nih.gov/pubmed/34289384
http://dx.doi.org/10.1016/j.celrep.2021.109450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270748/
https://www.ncbi.nlm.nih.gov/pubmed/34289384
http://dx.doi.org/10.1016/j.celrep.2021.109450

Ejemplares similares